- Price
- $8.30
- Day
- +6.14%
- Mkt Cap
- $345.63M
- 52W Range
- $2.71 – $8.70
- Volume
- 2.01M
- Beta
- 1.55
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026. Agenus plans to host a webcast later in August to discuss its corporate priorities, including the acceleration of the botensilimab and balstilimab (BOT+BAL) immunotherapy combination in the neoadjuvant colon cancer setting through the Phase 3 ROBBIN trial.
Read full article
Investors need to pay close attention to AGEN stock based on the movements in the options market lately.
Read full article
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer and advanced sarcoma, re.
Read full article